Help people with cancer
live longer and better.
About us
live longer and better.
Company Introduction
About 3D Medicines
3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.
OUR STRENGTHS
-
01
Unique strategy surrounding cancer chronicization
- Building unique eco-system and entry barrier surrounding cancer chronicization by leveraging our deep insights on patients, products and market
-
02
Diversified pipeline with multiple pillars
- subcutaneous injection PD-L1 mAb worldwide to meet the needs in a huge potential market
- Diversified late stage pipeline powered by mono and combo therapy, realizing deep synergy among products and targeting a broad patient group
-
03
Strong R&D capacity and complete quality system
- capable clinical team, envafolimab having submitted NDA in less than 4 years after the launch of Phase I trial, NDA is accepted by NMPA recently
- Complete capacity from pre-clinical discovery to commercialization, which can be quickly and efficiently expanded
-
04
Experienced and comprehensive management team
- Management team with rich experience, covering preclinical discovery, translational medicine, clinical development and commercialization
-
05
Global coverage
- China-based with global coverage, mobilize various resources while based in China
R&D team
-
R&D staff
We are devoted to building a high quality, and excellent, experienced team, but also pay attention to the training of young researchers. Among the total research and development personnel, master's degree accounts for 43%, and doctor's degree accounts for 10%. 24% of R&D employees are under 30 years old.
STRATEGIC PLANNING
Seizing the cancer chronicization trend, we develop next-generation anticancer solutions
with our backbone IO combination therapy
-
· Past ·Build Core Abilities- Establishing an international R&D team with rich experience and holistic approaches
- Discovering market and patient needs and developing corresponding therapies
- Developing and registering subcutaneous injection PD-L1 mAb worldwide
-
· Present ·Scale up- Commercializing through external production and sales partnerships
- Expanding the pipeline through in-house R&D and licensed-in assets
- Building self-production site, ensuring stable drug supply
-
· Near Future ·Become a Global Pharma- Accelerating clinical trials worldwide
- Penetrating international markets
- Building a global pharma integrating research, production, and marketing
